cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2022-3196cardiovascular-3196Research ArticleJOURNAL GLUB: НОВОСТИ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫJOURNAL GLUB: EVIDENCE-BASED MEDICINE NEWSЕще одно свидетельство против широкого применения антиагрегантов при лечении новой коронавирусной инфекции в стационаре, полученное в рандомизированном контролируемом исследованииAdditional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trialhttps://orcid.org/0000-0003-2816-1183ЯвеловИ. С.YavelovI. S.
Доктор медицинских наук, руководитель отдела фундаментальных и клинических проблем тромбоза при неинфекционных заболеваниях
Москва
Moscow
IYavelov@gnicpm.ruФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииNational Medical Research Center for Therapy and Preventive Medicine20222601202221231963196Copyright © Явелов И.С., 20222022Явелов И.С.Yavelov I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3196
.
.
COVID-19новая коронавирусная инфекцияантиагрегантыацетилсалициловая кислотаблокаторы P2Y12 рецептора тромбоцитовклопидогрелтикагрелорCOVID-19coronavirus infectionantiplatelet agentsacetylsalicylic acidP2Y12 inhibitorsclopidogrelticagrelorReferencesLeentjens J, van Haaps TF, Wessels PF, et al. COVID-19associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8(7):e524-33. doi:10.1016/S2352-3026(21)00105-8.Leentjens J, van Haaps TF, Wessels PF, et al. COVID-19associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8(7):e524-33. doi:10.1016/S2352-3026(21)00105-8.Barrett TJ, Cornwell M, Myndzar K, et al. Platelets amplify endotheliopathy in COVID-19. Sci Adv. 2021;7(37):eabh2434. doi:10.1126/sciadv.abh2434.Barrett TJ, Cornwell M, Myndzar K, et al. Platelets amplify endotheliopathy in COVID-19. Sci Adv. 2021;7(37):eabh2434. doi:10.1126/sciadv.abh2434.Martha JW, Pranata R, Lim MA, et al. Active prescription of lowdose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates. Int J Infect Dis. 2021;108:6-12. doi:10.1016/j.ijid.2021.05.016.Martha JW, Pranata R, Lim MA, et al. Active prescription of lowdose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates. Int J Infect Dis. 2021;108:6-12. doi:10.1016/j.ijid.2021.05.016.RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. Lancet. 2022;399(10320):143-151. doi:10.1016/S0140-6736(21)01825-0.RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. Lancet. 2022;399(10320):143-151. doi:10.1016/S0140-6736(21)01825-0.Berger JS, Kornblith LZ, Gong MN, et al., for the ACTIV-4a Investigators. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19. A Randomized Clinical Trial. JAMA. 2022;327:227-36. doi:10.1001/jama.2021.23605.Berger JS, Kornblith LZ, Gong MN, et al., for the ACTIV-4a Investigators. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19. A Randomized Clinical Trial. JAMA. 2022;327:227-36. doi:10.1001/jama.2021.23605.
The authors declare that there are no conflicts of interest present.